Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05599984
Title	Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	AbbVie
Indications	pancreatic endocrine carcinoma central nervous system cancer large cell neuroendocrine carcinoma neuroendocrine carcinoma glioblastoma IDH-mutant anaplastic astrocytoma lung small cell carcinoma gastrointestinal neuroendocrine tumor IDH-mutant and 1p/19q-codeleted oligodendroglioma prostate neuroendocrine neoplasm
Therapies	ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| ISR \| FRA \| ESP \| DEU \| AUS